Finoriq research workspace
Zura Bio Ltd (ZURA) Historical Metrics
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune. Review ZURA fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Company
- Zura Bio Ltd (ZURA)
- Ticker
- ZURA
- Market Cap
- $501.6M
- Latest Price
- $5.28
- Industry
- Biotech & Pharma
Zura Bio Ltd (ZURA) Current Valuation Metrics
Static valuation preview for Zura Bio Ltd (ZURA). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -13.1% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -12.4% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 5.16x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.